îæ€çŽ¢
îæ€çŽ¢
î
Novo Nordisk A/S
NVO36.480USD
-0.270-0.73%
çµå€Â 04/01, 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
122.90Bæ䟡ç·é¡
10.47çŽè¿12ã¶æPER
î
詳现æ å ± Novo Nordisk A/S äŒæ¥å
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Novo Nordisk A/Sã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒãNVO
äŒç€ŸåNovo Nordisk A/S
äžå Žæ¥May 17, 1974
æé«çµå¶è²¬ä»»è
ãCEOãDoustdar (Maziar Mike)
åŸæ¥å¡æ°76302
蚌åžçš®é¡Depository Receipt
決ç®ææ«May 17
æ¬ç€Ÿæåšå°Novo Alle 1
éœåžBAGSVAERD
蚌åžååŒæNASDAQ OMX NASDAQ Basic NYSE
åœDenmark
éµäŸ¿çªå·2880
é»è©±çªå·4544448888
ãŠã§ããµã€ãhttps://www.novonordisk.com/
äŒæ¥ã³ãŒãNVO
äžå Žæ¥May 17, 1974
æé«çµå¶è²¬ä»»è
ãCEOãDoustdar (Maziar Mike)
Novo Nordisk A/Sã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Lars Rebien Soerensen
Mr. Lars Rebien Soerensen
Chairman of the Board
Chairman of the Board
--
--
Ms. Liselotte Hyveled
Ms. Liselotte Hyveled
Director, Employee Representative
Director, Employee Representative
--
--
Mr. Maziar Mike Doustdar
Mr. Maziar Mike Doustdar
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Mr. Henrik Ehlers Wulff
Mr. Henrik Ehlers Wulff
Executive Vice President - Product Supply
Executive Vice President - Product Supply
--
--
Mr. Kasim Kutay
Mr. Kasim Kutay
Director
Director
--
--
Ms. Mette Boejer Jensen
Ms. Mette Boejer Jensen
Director, Employee Representative
Director, Employee Representative
--
--
Mr. Thomas Rantzau
Mr. Thomas Rantzau
Director, Employee Representative
Director, Employee Representative
--
--
Mr. Karsten Munk Knudsen
Mr. Karsten Munk Knudsen
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Ludovic Helfgott
Mr. Ludovic Helfgott
Executive Vice President - Product & Portfolio Strategy
Executive Vice President - Product & Portfolio Strategy
--
--
Dr. Martin Holst Lange
Dr. Martin Holst Lange
Executive Vice President, Chief Scientific Officer, Research & Development
Executive Vice President, Chief Scientific Officer, Research & Development
--
--
詳现ãèŠã
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Lars Rebien Soerensen
Mr. Lars Rebien Soerensen
Chairman of the Board
Chairman of the Board
--
--
Ms. Liselotte Hyveled
Ms. Liselotte Hyveled
Director, Employee Representative
Director, Employee Representative
--
--
Mr. Maziar Mike Doustdar
Mr. Maziar Mike Doustdar
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Mr. Henrik Ehlers Wulff
Mr. Henrik Ehlers Wulff
Executive Vice President - Product Supply
Executive Vice President - Product Supply
--
--
Mr. Kasim Kutay
Mr. Kasim Kutay
Director
Director
--
--
Ms. Mette Boejer Jensen
Ms. Mette Boejer Jensen
Director, Employee Representative
Director, Employee Representative
--
--
åçå èš³
é貚: USDæŽæ°æå»: Tue, Jan 6
é貚: USDæŽæ°æå»: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
äºæ¥å¥USD
äŒç€Ÿå
åç
æ¯ç
Total GLP-1
5.75B
49.00%
Obesity (Wegovy®)
3.19B
27.15%
Long-acting insulin
657.86M
5.60%
Fast-acting insulin
643.61M
5.48%
Rare blood disorders
457.21M
3.89%
ä»ã®
1.04B
8.88%
å°åå¥USD
äŒç€Ÿå
åç
æ¯ç
USA
6.44B
54.88%
Canada
2.63B
22.36%
Emerging Markets
1.04B
8.85%
APAC
856.16M
7.29%
Region China
777.53M
6.62%
äºæ¥å¥
å°åå¥
äºæ¥å¥USD
äŒç€Ÿå
åç
æ¯ç
Total GLP-1
5.75B
49.00%
Obesity (Wegovy®)
3.19B
27.15%
Long-acting insulin
657.86M
5.60%
Fast-acting insulin
643.61M
5.48%
Rare blood disorders
457.21M
3.89%
ä»ã®
1.04B
8.88%
æ ªäž»
æŽæ°æå»: Wed, Mar 4
æŽæ°æå»: Wed, Mar 4
æ ªäž»çµ±èš
çš®é¡
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Loomis, Sayles & Company, L.P.
0.51%
Putnam Investment Management, L.L.C.
0.43%
Capital International Investors
0.33%
Folketrygdfondet
0.30%
Fisher Investments
0.29%
ä»ã®
98.14%
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Loomis, Sayles & Company, L.P.
0.51%
Putnam Investment Management, L.L.C.
0.43%
Capital International Investors
0.33%
Folketrygdfondet
0.30%
Fisher Investments
0.29%
ä»ã®
98.14%
çš®é¡
æ ªäž»çµ±èš
æ¯ç
Investment Advisor
4.33%
Investment Advisor/Hedge Fund
2.61%
Research Firm
1.16%
Hedge Fund
0.62%
Pension Fund
0.33%
Bank and Trust
0.25%
Insurance Company
0.19%
Family Office
0.02%
Family Office
0.02%
ä»ã®
90.48%
æ©é¢æè³å®¶ä¿ææ ª
îæŽæ°æå»: Thu, Jan 1
æŽæ°æå»: Thu, Jan 1
å ±åæé
æ©é¢æè³å®¶æ°
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
2025Q4
2878
311.09M
9.23%
-12.60M
2025Q3
2793
305.60M
9.08%
-33.91M
2025Q2
2754
330.35M
9.82%
-31.19M
2025Q1
2769
336.08M
9.99%
-21.71M
2024Q4
2676
348.53M
10.35%
+330.19K
2024Q3
2529
339.29M
10.15%
-6.04M
2024Q2
2456
341.24M
10.21%
+6.87M
2024Q1
2291
330.25M
9.75%
+10.89M
2023Q4
2037
314.57M
9.30%
+1.47M
2023Q3
1826
307.14M
8.91%
+4.22M
詳现ãèŠã
æ ªäž»åå
îäŒç€Ÿå
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
å€åç
æ¥ä»
Loomis, Sayles & Company, L.P.
17.14M
0.51%
+969.92K
+6.00%
Dec 31, 2025
Putnam Investment Management, L.L.C.
14.39M
0.43%
+752.49K
+5.52%
Dec 31, 2025
Capital International Investors
11.21M
0.33%
-6.50M
-36.71%
Dec 31, 2025
Folketrygdfondet
10.16M
0.3%
-47.78K
-0.47%
Dec 31, 2025
Fisher Investments
9.78M
0.29%
-538.68K
-5.22%
Dec 31, 2025
Fidelity Management & Research Company LLC
8.56M
0.25%
-4.05M
-32.12%
Dec 31, 2025
Goldman Sachs & Company, Inc.
7.62M
0.23%
+4.37M
+134.56%
Dec 31, 2025
Citadel Advisors LLC
7.41M
0.22%
+4.28M
+136.62%
Dec 31, 2025
T. Rowe Price International Ltd
7.07M
0.21%
+2.21M
+45.64%
Dec 31, 2025
Managed Account Advisors LLC
6.94M
0.21%
-1.09M
-13.63%
Dec 31, 2025
詳现ãèŠã
é¢é£ETF
îæŽæ°æå»: Sat, Dec 6
æŽæ°æå»: Sat, Dec 6
éæå
æ¯ç
Roundhill GLP-1 & Weight Loss ETF
15.04%
VanEck Pharmaceutical ETF
14.55%
Amplify Weight Loss Drug & Treatment ETF
9.51%
The Opal International Dividend Income ETF
3.79%
TrueShares Low Volatility Equity Income ETF
3.21%
First Trust WCM International Equity ETF
2.68%
Invesco International Dividend Achievers ETF
1.8%
Putnam Focused Large Cap Value ETF
1.16%
SP Funds S&P World (ex-US) ETF
1.05%
ActivePassive International Equity ETF
0.95%
詳现ãèŠã
Roundhill GLP-1 & Weight Loss ETF
æ¯ç15.04%
VanEck Pharmaceutical ETF
æ¯ç14.55%
Amplify Weight Loss Drug & Treatment ETF
æ¯ç9.51%
The Opal International Dividend Income ETF
æ¯ç3.79%
TrueShares Low Volatility Equity Income ETF
æ¯ç3.21%
First Trust WCM International Equity ETF
æ¯ç2.68%
Invesco International Dividend Achievers ETF
æ¯ç1.8%
Putnam Focused Large Cap Value ETF
æ¯ç1.16%
SP Funds S&P World (ex-US) ETF
æ¯ç1.05%
ActivePassive International Equity ETF
æ¯ç0.95%
é åœé
îéå»5幎éã®é
åœéç·æ¯æé¡ã¯
18.01B
ç±³ãã«ã§ããã
æ¥ä»
é
åœé
æš©å©ç¢ºå®æ¥
æ¯ææ¥
é
åœèœã¡æ¥
Feb 04, 2026
NVO.NB Approximate final Cash Dividend of gross USD 1.275101 paid on Apr 08, 2026 going ex on Mar 30, 2026
Mar 30, 2026
Apr 08, 2026
Mar 30, 2026
Aug 06, 2025
NVO.NB Interim Cash Dividend of gross USD 0.58432 paid on Aug 26, 2025 going ex on Aug 18, 2025
Aug 18, 2025
Aug 26, 2025
Aug 18, 2025
Feb 06, 2025
NVO.NB Final Cash Dividend of gross USD 1.142561 paid on Apr 08, 2025 going ex on Mar 31, 2025
Mar 31, 2025
Apr 08, 2025
Mar 31, 2025
Aug 06, 2024
NVO.NB Final Cash Dividend of gross USD 0.516902 paid on Aug 26, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Aug 26, 2024
Aug 16, 2024
Jan 31, 2024
NVO.NB Interim Cash Dividend of gross USD 0.929335 paid on Apr 02, 2024 going ex on Mar 22, 2024
Mar 25, 2024
Apr 02, 2024
Mar 22, 2024
Aug 10, 2023
NVO.NB Interim Cash Dividend of gross USD 0.876339 paid on Aug 29, 2023 going ex on Aug 18, 2023
Aug 21, 2023
Aug 29, 2023
Aug 18, 2023
Feb 02, 2023
NVO.NB Final Cash Dividend of gross USD 1.180581 paid on Apr 04, 2023 going ex on Mar 24, 2023
Mar 27, 2023
Apr 04, 2023
Mar 24, 2023
Aug 04, 2022
NVO.NB Interim Cash Dividend of gross USD 0.577745 paid on Aug 23, 2022 going ex on Aug 12, 2022
Aug 15, 2022
Aug 23, 2022
Aug 12, 2022
Mar 02, 2022
NVO.NB Interim Cash Dividend of gross USD 1.022424 paid on Apr 05, 2022 going ex on Mar 25, 2022
Mar 28, 2022
Apr 05, 2022
Mar 25, 2022
Aug 05, 2021
NVO.NB Interim Cash Dividend of gross USD 0.550289 paid on Aug 25, 2021 going ex on Aug 16, 2021
Aug 17, 2021
Aug 25, 2021
Aug 16, 2021
詳现ãèŠã
æ ªåŒåå²
îæ¥ä»
é
åœèœã¡æ¥
çš®é¡
æ¯ç
Aug 14, 2023
Split
1â2
æ¥ä»
é
åœèœã¡æ¥
çš®é¡
æ¯ç
Aug 14, 2023
Split
1â2
